OVERVIEW
Because drug expenses represent a significant part of health care costs, it is a strategic necessity to monitor the pharmaceutical pipeline. Knowledge of upcoming new drug classes or new products to compete with established products is needed to plan a discussion on a drug’s formulary status and to develop special procedures for monitoring or limiting availability. An expensive injectable biologic that requires special monitoring and is only available through a limited distribution network will not only impact a pharmacy’s drug budget but also personnel to procure the drug and manage it. By knowing whether other drugs in the same class or more convenient administration may become available soon, a plan can be developed to meet the needs for a patient population. Justifications can be developed to implement incremental value–based formulary decisions and restricted access, or to plan for value-based negotiations for the new drug.
The need to monitor the pharmaceutical pipeline can be seen in the topics inclusion in national meetings and publications. The annual drug expenditures report by American Society of Health-System Pharmacists (ASHP; Rx Forecast) regularly includes a section of new drugs projected to be approved in the next year. The Academy of Managed Care Pharmacy meetings include multiple presentations on the pharmaceutical pipeline. Presentations are divided into conventional drugs, specialty medications, and high-cost therapeutic areas.
Various methods to monitor the pharmaceutical pipeline have been used over the years. Simple lists and spreadsheets provide some basic information. Some very in-depth and costly services are also available that provide analyses by health care professionals, researchers, and lawyers of a drug’s potential impact. Hospital Pharmacy carries well-written and researched reviews of new drugs from the Formulary Monograph Service in each issue. Beginning in June 2017, our Founder, Scot Walker, Pharm.D., started providing a brief review of a drug class or therapeutic class in Hospital Pharmacy. Using information from Prescribe Right’s Pharmaceutical Pipeline Tracker database, each review gives a snapshot of a group of potential new drugs in late stages of development. The reviews are designed to keep you informed about drugs in development that you will be discussing.
The Pharmaceutical Pipeline Tracker is the result of extensive daily research by Dr. Walker. Scot is an accomplished entrepreneurial healthcare executive with management and patient care experience. He has a record of effecting change in pharmaceutical market share and generating new revenue streams through innovative marketing programs and creation of new services. His analyses of drug safety and efficacy and evidenced based medicine principles have provided the basis for strategic planning and changes in patient care.
Scot reviews over 200 data feeds from around the industry concerning investigational drugs. Of the 604 investigational drugs in our knowledgebase, 20 were added during the first six months of 2018. There are twenty-six drugs with published PDUFA dates between September 2018 and the end of May 2019. We have populated the knowledge base with over 700 citations, conclusions from published studies, news and analysis for drugs in the knowledge base such as FDA actions and analyst’s forecasts. These are accessible via URL links to display the full abstract with all the functionality of a PubMed abstract.
USE Case - Monitoring Drugs with PDUFA Dates
USE CASE – Monitoring Investigational Drugs by Indication
USE CASE - Right to Try research via Pharmaceutical Pipeline Tracker’s Single Drug Search
Because drug expenses represent a significant part of health care costs, it is a strategic necessity to monitor the pharmaceutical pipeline. Knowledge of upcoming new drug classes or new products to compete with established products is needed to plan a discussion on a drug’s formulary status and to develop special procedures for monitoring or limiting availability. An expensive injectable biologic that requires special monitoring and is only available through a limited distribution network will not only impact a pharmacy’s drug budget but also personnel to procure the drug and manage it. By knowing whether other drugs in the same class or more convenient administration may become available soon, a plan can be developed to meet the needs for a patient population. Justifications can be developed to implement incremental value–based formulary decisions and restricted access, or to plan for value-based negotiations for the new drug.
The need to monitor the pharmaceutical pipeline can be seen in the topics inclusion in national meetings and publications. The annual drug expenditures report by American Society of Health-System Pharmacists (ASHP; Rx Forecast) regularly includes a section of new drugs projected to be approved in the next year. The Academy of Managed Care Pharmacy meetings include multiple presentations on the pharmaceutical pipeline. Presentations are divided into conventional drugs, specialty medications, and high-cost therapeutic areas.
Various methods to monitor the pharmaceutical pipeline have been used over the years. Simple lists and spreadsheets provide some basic information. Some very in-depth and costly services are also available that provide analyses by health care professionals, researchers, and lawyers of a drug’s potential impact. Hospital Pharmacy carries well-written and researched reviews of new drugs from the Formulary Monograph Service in each issue. Beginning in June 2017, our Founder, Scot Walker, Pharm.D., started providing a brief review of a drug class or therapeutic class in Hospital Pharmacy. Using information from Prescribe Right’s Pharmaceutical Pipeline Tracker database, each review gives a snapshot of a group of potential new drugs in late stages of development. The reviews are designed to keep you informed about drugs in development that you will be discussing.
The Pharmaceutical Pipeline Tracker is the result of extensive daily research by Dr. Walker. Scot is an accomplished entrepreneurial healthcare executive with management and patient care experience. He has a record of effecting change in pharmaceutical market share and generating new revenue streams through innovative marketing programs and creation of new services. His analyses of drug safety and efficacy and evidenced based medicine principles have provided the basis for strategic planning and changes in patient care.
Scot reviews over 200 data feeds from around the industry concerning investigational drugs. Of the 604 investigational drugs in our knowledgebase, 20 were added during the first six months of 2018. There are twenty-six drugs with published PDUFA dates between September 2018 and the end of May 2019. We have populated the knowledge base with over 700 citations, conclusions from published studies, news and analysis for drugs in the knowledge base such as FDA actions and analyst’s forecasts. These are accessible via URL links to display the full abstract with all the functionality of a PubMed abstract.
USE Case - Monitoring Drugs with PDUFA Dates
USE CASE – Monitoring Investigational Drugs by Indication
USE CASE - Right to Try research via Pharmaceutical Pipeline Tracker’s Single Drug Search
Services |
Company |
Support |
© COPYRIGHT 2015. ALL RIGHTS RESERVED.
|